Patents by Inventor Ignacio Muñoz-Sanjuán

Ignacio Muñoz-Sanjuán has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11421007
    Abstract: The present disclosure is in the field of modulation of Htt gene expression and HTT protein levels.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: August 23, 2022
    Assignees: Sangamo Therapeutics, Inc., CHDI Foundation, Inc.
    Inventors: Steven Froelich, Ignacio Munoz-Sanjuan, Edward J. Rebar, Bryan Zeitler, H. Steve Zhang
  • Patent number: 11279739
    Abstract: The present disclosure is in the field of modulation of Htt gene expression and HTT protein levels.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: March 22, 2022
    Assignees: Sangamo Therapeutics, Inc., CHDI Foundation, Inc.
    Inventors: Steven Froelich, Ignacio Munoz-Sanjuan, Edward J. Rebar, Bryan Zeitler, H. Steve Zhang
  • Patent number: 11110154
    Abstract: Disclosed herein are methods and compositions for treating or preventing Huntington's Disease.
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: September 7, 2021
    Assignees: Sangamo Therapeutics, Inc., CHDI Foundation, Inc.
    Inventors: Steven Froelich, Seung Kwak, Ignacio Munoz-Sanjuan, H. Steve Zhang
  • Patent number: 10457675
    Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: October 29, 2019
    Assignee: CHDI Foundation, Inc.
    Inventors: Celia Dominguez, Ignacio Muñoz-Sanjuán, Roland W. Bürli, Christopher A. Luckhurst, Daniel R. Allen, Gilles Raphy, Perla Breccia, Alan F. Haughan, Grant Wishart, Samantha J. Hughes, Rebecca E. Jarvis, Huw D. Vater, Stephen D. Penrose, Michael Wall, Andrew J. Stott, Elizabeth A. Saville-Stones
  • Publication number: 20190322711
    Abstract: The present disclosure is in the field of modulation of Htt gene expression and HTT protein levels.
    Type: Application
    Filed: April 17, 2019
    Publication date: October 24, 2019
    Inventors: Steven Froelich, Ignacio Munoz-Sanjuan, Edward J. Rebar, Bryan Zeitler, H. Steve Zhang
  • Patent number: 10258621
    Abstract: Certain adjunctive therapies comprising a kynurenine-3-monooxygenase inhibitor and an antiviral agent for treating HIV-related disorders are provided herein. These disorders include AIDS dementia complex, AIDS-induced encephalopathy, HIV-associated neurocognitive disorder, asymptomatic neurocognitive impairment, minor neurocognitive disorder, minor cognitive motor disorder, vacuolar myelopathy, peripheral neuropathies, and polymyositis. Also provided are pharmaceutical compositions comprising a kynurenine-3-monooxygenase inhibitor and an antiviral agent.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: April 16, 2019
    Assignee: CHDI Foundation, Inc.
    Inventors: Celia Dominguez, Ignacio Muñoz-Sanjuán, Leticia Toledo-Sherman
  • Publication number: 20190062321
    Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use.
    Type: Application
    Filed: July 30, 2018
    Publication date: February 28, 2019
    Inventors: Celia Dominguez, Ignacio Muñoz-Sanjuán, Roland W. Bürli, Christopher A. Luckhurst, Daniel R. Allen, Gilles Raphy, Perla Breccia, Alan F. Haughan, Grant Wishart, Samantha J. Hughes, Rebecca E. Jarvis, Huw D. Vater, Stephen D. Penrose, Michael Wall, Andrew J. Stott, Elizabeth A. Saville-Stones
  • Patent number: 10106535
    Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: October 23, 2018
    Assignee: CHDI FOUNDATION, INC.
    Inventors: Celia Dominguez, Ignacio Muñoz-Sanjuán, Michel Maillard, Christopher A. Luckhurst, Rebecca E. Jarvis, Roland W. Bürli, Daniel R. Allen, Alan F. Haughan, Perla Breccia, Huw D. Vater, Andrew J. Stott, Stephen D. Penrose, Michael Wall, Elizabeth A. Saville-Stones, Grant Wishart, Samantha J. Hughes
  • Patent number: 10105363
    Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: October 23, 2018
    Assignee: CHDI foundation, Inc.
    Inventors: Celia Dominguez, Vahri Beaumont, Ignacio Muñoz-Sanjuán, Roland W. Bürli, Alan F. Haughan, Christopher A. Luckhurst, Michael Wall, Gilles Raphy, Beth Thomas
  • Patent number: 10065948
    Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use. The condition or disorder mediated by HDAC comprises a neurodegenerative pathology. Accordingly, also provided is a method of treating a neurodegenerative pathology mediated by HDAC in a subject in need of such a treatment, comprising administering to the subject a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt thereof, described herein.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: September 4, 2018
    Assignee: CHDI Foundation, Inc.
    Inventors: Celia Dominguez, Ignacio Muñoz-Sanjuán, Roland W. Bürli, Christopher A. Luckhurst, Daniel R. Allen, Gilles Raphy, Perla Breccia, Alan F. Haughan, Grant Wishart, Samantha J. Hughes, Rebecca E. Jarvis, Huw D. Vater, Stephen D. Penrose, Michael Wall, Andrew J. Stott, Elizabeth A. Saville-Stones
  • Patent number: 9981918
    Abstract: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
    Type: Grant
    Filed: August 28, 2012
    Date of Patent: May 29, 2018
    Assignee: CHDI Foundation, Inc.
    Inventors: Leticia M. Toledo-Sherman, Celia Dominguez, Michael Prime, Peter Johnson, Ignacio Muñoz-Sanjuán, Stephen Martin Courtney, William Mitchell, Christopher John Brown, Paula C. De Aguiar Pena
  • Publication number: 20170305900
    Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.
    Type: Application
    Filed: April 7, 2017
    Publication date: October 26, 2017
    Inventors: Celia Dominguez, Ignacio Muñoz-Sanjuán, Michel Maillard, Christopher A. Luckhurst, Rebecca E. Jarvis, Roland W. Bürli, Daniel R. Allen, Alan F. Haughan, Perla Breccia, Huw D. Vater, Andrew J. Stott, Stephen D. Penrose, Michael Wall, Elizabeth A. Saville-Stones, Grant Wishart, Samantha J. Hughes
  • Patent number: 9783488
    Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: October 10, 2017
    Assignee: CHDI Foundation, Inc.
    Inventors: Celia Dominguez, Ignacio Muñoz-Sanjuán, Michel Maillard, Gilles Raphy, Alan F. Haughan, Christopher A. Luckhurst, Rebecca E. Jarvis, Roland W. Bürli, Perla Breccia, Grant Wishart, Samantha J. Hughes, Daniel R. Allen, Stephen D. Penrose
  • Patent number: 9765054
    Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.
    Type: Grant
    Filed: January 23, 2012
    Date of Patent: September 19, 2017
    Assignee: CHDI Foundation, Inc.
    Inventors: Roland W. Bürli, Andrew J. Stott, Perla Breccia, Celia Dominguez, Ignacio Muñoz-Sanjuàn, Christopher A. Luckhurst, Samantha J. Hughes, Alan F. Haughan
  • Publication number: 20170224684
    Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.
    Type: Application
    Filed: January 20, 2017
    Publication date: August 10, 2017
    Inventors: Celia Dominguez, Vahri Beaumont, Ignacio Muñoz-Sanjuán, Roland W. Bürli, Alan F. Haughan, Christopher A. Luckhurst, Michael Wall, Gilles Raphy, Beth Thomas
  • Publication number: 20170209440
    Abstract: Certain adjunctive therapies comprising a kynurenine-3-monooxygenase inhibitor and an antiviral agent for treating HIV-related disorders are provided herein. These disorders include AIDS dementia complex, AIDS-induced encephalopathy, HIV-associated neurocognitive disorder, asymptomatic neurocognitive impairment, minor neurocognitive disorder, minor cognitive motor disorder, vacuolar myelopathy, peripheral neuropathies, and polymyositis. Also provided are pharmaceutical compositions comprising a kynurenine-3-monooxygenase inhibitor and an antiviral agent.
    Type: Application
    Filed: July 17, 2015
    Publication date: July 27, 2017
    Inventors: Celia Dominguez, Ignacio Muñoz-Sanjuan, Leticia Toledo-Sherman
  • Publication number: 20170101402
    Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use. The condition or disorder mediated by HDAC comprises a neurodegenerative pathology. Accordingly, also provided is a method of treating a neurodegenerative pathology mediated by HDAC in a subject in need of such a treatment, comprising administering to the subject a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt thereof, described herein.
    Type: Application
    Filed: June 1, 2015
    Publication date: April 13, 2017
    Inventors: Celia Dominguez, Ignacio Muñoz-Sanjuán, Christopher A. Luckhurst, Daniel R. Allen, Gilles Raphy, Roland W. Bürli, Perla Breccia, Alan F. Haughan, Grant Wishart, Samantha J. Hughes, Rebeca E. Jarvis, Huw D. Vater, Stephen D. Penrose, Michael Wall, Andrew J. Stott, Elizabeth A. Saville-Stones
  • Patent number: 9617259
    Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: April 11, 2017
    Assignee: CHDI Foundation, Inc.
    Inventors: Celia Dominguez, Ignacio Muñoz-Sanjuán, Michel Maillard, Christopher A. Luckhurst, Rebecca E. Jarvis, Roland W. Bürli, Daniel R. Allen, Alan F. Haughan, Perla Breccia, Huw D. Vater, Andrew J. Stott, Stephen D. Penrose, Michael Wall, Elizabeth A. Saville-Stones, Grant Wishart, Samantha J. Hughes
  • Patent number: 9562021
    Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: February 7, 2017
    Assignee: CHDI Foundation, Inc.
    Inventors: Celia Dominguez, Vahri Beaumont, Ignacio Muñoz-Sanjuán, Roland W. Bürli, Alan F. Haughan, Christopher A. Luckhurst, Michael Wall, Gilles Raphy, Beth Thomas
  • Patent number: 9428464
    Abstract: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
    Type: Grant
    Filed: August 28, 2012
    Date of Patent: August 30, 2016
    Assignee: CHDI Foundation, Inc.
    Inventors: Stephen Martin Courtney, Michael Prime, William Mitchell, Christopher John Brown, Paula C. De Aguiar Pena, Peter Johnson, Celia Dominguez, Leticia M. Toledo-Sherman, Ignacio Muñoz-Sanjuan